Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts

Market Focus

May 29

On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.

The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.

Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.

Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188168589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188168589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188168589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188168589","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts","media":"Market Focus","content":"<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1188168589","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188168589","pubTimestamp":1780026619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"异动快讯|亚盛医药常规交易涨6.35%B标移除里程碑叠加ASCO催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}